mrjСовременная ревматологияModern Rheumatology Journal1996-70122310-158XIMA-PRESS, LLC10.14412/1996-7012-2014-4-96-102mrj-582Research ArticleИНФОРМАЦИЯINFORMATION«ГОРЯЧИЕ» ТЕМЫ СОВРЕМЕННОЙ РЕВМАТОЛОГИИHot topics in modern rheumatologyКаратеевД. Е.KarateevD. E.

Д.м.н.

34A, Kashirskoe Shosse, Moscow Russia 115552

aekarateev@rambler.ruАлександроваЕ. Н.AleksandrovaE. N.

Д.м.н.

34A, Kashirskoe Shosse, Moscow Russia 115552

aekarateev@rambler.ruФГБНУ «ННИИР им. В.А. Насоновой»РоссияV.A. Nasonova Research Institute of RheumatologyRussian Federation2014031220148496102Copyright © Каратеев Д.Е., Александрова Е.Н., 20142014Каратеев Д.Е., Александрова Е.Н.Karateev D.E., Aleksandrova E.N.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://mrj.ima-press.net/mrj/article/view/58214–15 октября 2014 г

14–15 октября 2014 г. в Москве, в рамках ежегодной научно-практической конференции ФГБНУ «НИИР им. В.А. Насоновой» «Коморбидность при ревматических заболеваниях», прошли Экспертный совете (ЭС) по препарату тофацитиниб (ТОФА) и два симпозиума – «Новые возможности таргетной терапии ревматоидного артрита» и «Слагаемые успеха терапии генно-инженерными биологическими препаратами при ревматических заболеваниях»

The Expert Council for Tofacitinib (TOFA) and two symposiums on New Possibilities for Targeted Therapy of Rheumatoid Arthritis and on Success Factor of Biological Therapy for Rheumatic Diseases were held within the annual scientific-and-practical conference of the V.A. Nasonova Research Institute of Rheumatology on Comorbidity in Rheumatic Diseases in Moscow on 14–15 October 2014.

ReferencesCharles-Schoeman C, Wicker P, Sechtem U, et al. Cardiovascular safety findings in rheumatoid arthritis patients treated with tofacitinib (CP-690,550), a novel, oral Jak inhibitor. THU0136, EULAR 2012.Charles-Schoeman C, Wicker P, Sechtem U, et al. Cardiovascular safety findings in rheumatoid arthritis patients treated with tofacitinib (CP-690,550), a novel, oral Jak inhibitor. THU0136, EULAR 2012.Cohen S, Tanaka Y, Mariettee X, et al. Integrated Safety Analysis of Tofacitinib in RA Clinical Trials with a Cumulative Exposure of 12664 Patient-years. OP0154. 2014. DOI: 10.1136/annrheumdis-2014-eular.5656.Cohen S, Tanaka Y, Mariettee X, et al. Integrated Safety Analysis of Tofacitinib in RA Clinical Trials with a Cumulative Exposure of 12664 Patient-years. OP0154. 2014. DOI: 10.1136/annrheumdis-2014-eular.5656.FDA Advisory Committee Meeting, 9 May 2012 (NDA 203214). Briefing book. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ArthritisAdvisoryCommittee/UCM302960.pdfFDA Advisory Committee Meeting, 9 May 2012 (NDA 203214). Briefing book. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ArthritisAdvisoryCommittee/UCM302960.pdfFDA Advisory Committee Meeting, 9 May 2012 (NDA 203214). Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ArthritisAdvisoryCommittee/UCM304200.pdfFDA Advisory Committee Meeting, 9 May 2012 (NDA 203214). Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ArthritisAdvisoryCommittee/UCM304200.pdf

The authors declare that there are no conflicts of interest present.